Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/11/2025

Management of Dapsone-Induced Pancytopenia

Immediate Actions

  • The American Society of Clinical Oncology recommends immediate discontinuation of dapsone and initiation of supportive care with corticosteroids (prednisone 1-2 mg/kg/day) upon detection of pancytopenia 1
  • Grade 3-4 pancytopenia requires hospital admission, and immediate hematology consultation is necessary for all cases of Grade 2 or higher 1

Diagnostic Workup

  • Essential laboratory evaluation includes complete blood count with differential, peripheral smear for morphology, reticulocyte count, LDH, haptoglobin, bilirubin (direct and indirect), and free hemoglobin to assess for concurrent hemolysis 1
  • The American Academy of Dermatology recommends checking G6PD level if not previously checked, especially in patients with a history of hemolysis 2

Pharmacologic Management

  • The American Society of Clinical Oncology recommends prednisone 1-2 mg/kg/day orally or IV equivalent, depending on severity, and continuing until blood counts recover, then tapering gradually 1

Supportive Care

  • The American Society of Clinical Oncology recommends RBC transfusion per existing guidelines, transfusing the minimum units necessary to relieve symptoms or achieve safe hemoglobin (7-8 g/dL in stable, non-cardiac inpatients) 1
  • The British Association of Dermatologists recommends monitoring closely for respiratory, cardiovascular, and other infections 4

Long-Term Considerations

  • Dapsone is permanently contraindicated after pancytopenia develops, and other sulfonamide-containing medications should be avoided due to cross-reactivity risk 1, 3
  • The American Society of Hematology recommends considering alternative second-line agents, such as rituximab, thrombopoietin receptor agonists (romiplostim, eltrombopag), azathioprine, cyclosporine, or mycophenolate mofetil, for underlying conditions like chronic ITP 5, 6